Ibrutinib inhibits CXCL12-/CXCL13-activated adhesion and migration of MCL cells. (A) Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCĪ³2, pAKT, pERK, and pJNK. (B-C) Mino or Jeko1 cells were treated with 100 nM ibrutinib and subjected to adhesion assays on plates precoated with (B) CXCL12 or CXCL13 and fibronectin or (C) VCAM-1. The n values represent the number of independent experiments performed in triplicate; the average of these experiments are displayed. (D) Cells from MCL cell lines Mino, Jeko1, and JVM-1 were treated with increasing concentration of ibrutinib and subjected to a chemotaxis migration assay in transwell plates with filters coated with VCAM-1, and CXCL12 or CXCL13 was added into the lower chamber as a chemoattractant. Ibrutinib dose-dependently inhibited CXCL12- and CXCL13-mediated migration of Mino cells, and CXCL12-mediated migration of Jeko1 and JVM-1 cells. *P < .05; **P < .01; ***P < .001. One-way ANOVA compared with vehicle control.
